Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest MedImmune Stories

2011-06-16 02:26:00

NESS ZIONA, Israel, June 16, 2011 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) [http://www.biondvax.com ] today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine. The vaccine was found to be safe and well tolerated, and induced robust immune responses, successfully meeting both the primary safety and immunogenicity endpoints, as well as additional secondary immunogenicity endpoints. It was also...

2011-06-08 06:00:00

- All tested doses were found safe and well-tolerated - - A single dose of 5 µg met the 3 CHMP immunogenicity criteria - QUEBEC CITY, June 8, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive results from a U.S. Phase I human clinical trial with its seasonal influenza vaccine...

2011-06-06 12:40:00

124 current and former female employees will share in settlement involving equal pay PHILADELPHIA, June 6, 2011 /PRNewswire-USNewswire/ -- AstraZeneca, one of the largest pharmaceutical companies in the world, will pay $250,000 to 124 women who were subjected to pay discrimination while working at the corporation's Philadelphia Business Center in Wayne, Pa. The action resolves a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against...

2011-06-06 11:24:00

STAMFORD, Conn., June 6, 2011 /PRNewswire-USNewswire/ -- AmeriCares has awarded its annual Power of Partnership Award to AstraZeneca for its outstanding commitment to increasing access to health care for people in need both here at home and throughout the developing world. In the past year alone, the pharmaceutical company renewed its support for the only breast cancer treatment program for Cambodia's poor, assembled over 14,000 hygiene kits for disaster survivors and, for the second year...

2011-05-31 02:00:00

ALDERLEY PARK and WELWYN GARDEN CITY, England, May 31, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). GPCRs are among the largest and most important family of proteins found in the human body, yet they become highly unstable when removed from their natural membrane-bound environments. This...

2011-05-13 09:00:00

GAITHERSBURG, Md., May 13, 2011 /PRNewswire/ -- MedImmune announced today it will present eight abstracts at the American Thoracic Society (ATS) International Conference in Denver, CO, May 13-18, 2011. "These data advance our understanding of thoracic diseases, highlighting our continued commitment to help improve patient health," said Bing Yao, Senior Vice President and Leader of the RIA innovative Medicines Unit (iMED) at MedImmune. MedImmune abstracts to be presented at the ATS...

2011-05-10 08:00:00

SAN DIEGO, May 10, 2011 /PRNewswire/ -- Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology(TM) platform, announced today a three year strategic collaboration with MedImmune LLC, the global biologics business of AstraZeneca. The agreement provides MedImmune with non-exclusive access to Pfenex Expression Technology and scientific resources for the development of bioprocesses for human therapeutic proteins and vaccines. Pfenex Inc. will engineer...

2011-05-09 07:00:00

ROCKVILLE, Md., May 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, 2011. The company reported a net loss of $7.5 million, or $0.07 per share, for the first quarter of 2011, compared to a net loss of $10.3 million, or $0.10 per share, for the first quarter of 2010. The primary reason for the decreased loss during the quarter was due to lower research and development spending to support clinical trials of the...

2011-05-03 06:30:00

SOUTH SAN FRANCISCO, Calif., May 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2011. For the first quarter of 2011, Rigel reported a net loss of $20.8 million, or $0.40 per share, compared to a net loss of $22.3 million, or $0.43 per share, in the first quarter of 2010. Weighted average shares outstanding for the first quarter of 2011 and 2010 were 52.3 million and 52.0 million, respectively. There...

2011-05-01 08:00:00

GAITHERSBURG, Md., May 1, 2011 /PRNewswire/ -- MedImmune announced today it will present 11 abstracts at the Pediatric Academic Societies (PAS) Meeting at the Colorado Convention Center in Denver, CO, April 30 - May 3, 2011. These abstracts advance the body of existing data and knowledge surrounding influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune's continued leadership in patient health. MedImmune abstracts to be presented at PAS regarding influenza...